Cytokine-regulated accumulation of eosinophils in inflammatory disease

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 59, Issue 8, 2004, Pages 793-805

  Lampinen, M ^a   Carlson, M ^a   Hakansson L D ^a   Venge, P ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allergy; Asthma; IBD; Inflammation; Migration; Ulcerative colitis

Indexed keywords

ALLERGEN; APOPTOSIS INHIBITOR; CELL ADHESION MOLECULE; CHEMOATTRACTANT; CHEMOTACTIC FACTOR; CYTOKINE; CYTOKINE RECEPTOR; EOTAXIN; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; SERUM ALBUMIN; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ALLERGY; APOPTOSIS; ASTHMA; BLOOD; BONE MARROW; CELL ADHESION; CELL COUNT; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CHEMOTAXIS; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; EOSINOPHIL; EOSINOPHILIA; EPITHELIUM CELL; EXTRAVASATION; HEMATOPOIESIS; HUMAN; INFLAMMATORY DISEASE; MAST CELL; MUCOSA INFLAMMATION; PRIORITY JOURNAL; REVIEW; TH2 CELL; ULCERATIVE COLITIS; UPREGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; ASTHMA; CELL ADHESION; CELL MOVEMENT; CHEMOTAXIS; COLITIS, ULCERATIVE; CYTOKINES; EOSINOPHILS; HUMANS; SERUM ALBUMIN;

EID: 3442896883     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2004.00469.x     Document Type: Review

References (151)

1. CAPRON M. Dual function of eosinophils in pathogenesis and protective immunity against parasites. Mem Inst Oswaldo Cruz 1992;87:83-89.
2. DAHL R, VENGE P, FREDENS K. Eosinophils. In: BARNES PJ, ed. Asthma: basic mechanisms and clinical management. London: Academic Press, 1992:111-124.
3. SILBERSTEIN DS. Eosinophil function in health and disease. Crit Rev Oncol Hematol 1995;19:47-77.
4. MAKIYAMA K, ZEA-IRIARTE W, TSUJI X. Activation of eosinophils in the pathophysiology of ulcerative colitis. J Gastroenterol 1995;30:64-69.
5. SPRY CJF. Chapters 1, 4, 5, 6, 15. In: Eosinophils. A comprehensive review and guide to the scientific and medical literature. Oxford: Oxford University Press, 1988.
6. KROEGEL C, VIRCHOW J-C, LUTTMAN W, WALKER C, WARNER JA. Pulmonary immune cells in health and disease: the eosinophil leukocyte (part 1). Eur Respir J 1994;7:519-543.
7. TRIGGIANI M, CALABRESE C, GRANATA F, GENTILE M, MARONE G. Metabolism of lipid mediators in human eosinophils. In: MARONE G, ed. Human eosinophils. Biological and clinical aspects. Basel: Kargel, 2000:77-98.
8. MIYAJIMA A, MUI AL-F, OGOROCHI T, SAKAMAKI K. Receptors for granulecyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. Blood 1993;82:1960-1974.
9. GOUNNI AS, GREGORY B, NUTKU E, ARIS F, LATIFA K, MINSHALL E et al. Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood 2000;96:2163-2171.
10. YING S, MENG Q, KAY AB, ROBINSON DS. Elevated expression of interleukin-9 mRNA in the bronchial mucosa of atopic asthmatics and allergen-induced cutaneous late-phase reaction: relationships to eosinophils, mast cells and T lymphocytes. Clin Exp Allergy 2002;32:866-871.
11. GORDON JR, SWYSTUN VA, LI F, ZHANG X, DAVIS BE, HULL P et al. Regular salbutamol use increases CXCL8 responses in asthma: relationship to the eosinophil response. Eur Respir J 2003;22:118-126.
12. PETERING H, GÖTZE O, KIMMIG D, SMOLARSKI R, KAPP A, ELSNER J. The biologic role of interleukin-8: functional analysis and expression of CXCR1 and CXCR2 on human eosinophils. Blood 1999;93:694-702.
13. NAGASE H, MIYAMASU M, YAMAGUCHI M, KAWASAKI H, OHTA K, YAMAMOTO K et al. Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils. J Allergy Clin Immunol 2000;106:1132-1139.
14. MURPHY PM, ROTHENBERG ME. Chemokine receptors. In: ROTHENBERG ME, ed. Chemokines in allergic disease. New York: Marcel Dekker, 2000:53-66.
15. ELSNER J, KAPP A. Actvator of human eosinophil effector functions by CC chemokines. Allergy Asthma Proc 1999;20:365-369.
16. YING S, KAY AB. Chemokines in allergic asthma. In: ROTHENBERG ME, ed. Chemokines in allergic diseases. New York: Marcel Dekker, 2000:383-401.
17. CURFS JHAJ, MEIS JFGM, HOOGKAMP-KORSTANJE JAA. A primer on cytokines: sources, receptors, effects and inducers. Clin Microbiol Rev 1997;10:742-780.
18. MENZIES-GOW A, YING S, SABROE I, STUBBS VL, SOLER D, WILLIAMS TJ et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 2002;169:2712-2728.
19. RAND TH, SILBERSTEIN DS, KORNFELD H, WELLER PF. Human eosinophils express functional interleukin 2 receptors. J Clin Invest 1991;88:825-832.
20. PLUMAS J, GRUART V, ALDEBERT D, TRUONG MJ, CAPRON M, CAPRON A et al. Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 interleukin 2 receptor subunit. Eur J Immunol 1991;21:1265-1270.
21. SIMON H-U, PLÖTZ S, SIMON D, SEITZER U, BRAATHEN LR, MENZ G et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol 2003;33:834-839.
22. MOQBEL R, LEVI-SCHAFFER F, KAY AB, Cytokine generation by eosinophils. J Allergy Clin Immunol 1994;94:1183-1188.
23. MIYAMASU M, HIRAI K, TAKAHASHI Y, IIDA M, YAMAGUCHI M, KOSHINO T et al. Chemotactic agonists induce cytokine generation in eosinophils. J Immunol 1995;154:1339-1349.
24. NAKAJIMA H, GLEICH GJ, KITA H. Constitutive production of IL-4 and IL-10 and stimulated production of IL-8 by normal peripheral blood eosinophils. J Immunol 1996;156:4859-4866.
25. SCHMID-GRENDELMEIER P, ALTZNAUER F, FISCHER B, BIZER C, STRAUMANN A, MENZ G et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 2002;169:1021-1027.
26. WELLER PF, RANDTH, BARRETT T, ELOVIC A, WONG DT, FINBERG RW. Accessory cell function of human eosinophils. HLA-DR-dependent, MHC- restricted antigen-presentation and IL-1 alpha expression. J Immunol 1993;150:2554-2562.
27. BOSSÉ M, AUDETTE M, FERLAND C, PELLETIER G, CHU HW, DAKHAMA A et al. Gene expression of interleukin-2 in purified human peripheral blood eosinophils. Immunology 1996;87:149-154.
28. LEVI-SCHAFFER F, BARKANS J, NEWMAN TM, YING S, WAKELIN M, HOHENSTEIN R et al. Identification of interleukin-2 in human peripheral blood eosinophils. Immunol 1996;87:155-161.
29. WOERLY G, ROGER N, LOISEAU S, CAPRON M. Expression of Th1 and Th2 immunoregulatory cytokines by human eosinophils. Int Arch Allergy Immunol 1999;118:95-97.
30. KITA H, OHNISHI T, OKUBO Y, WEILER D, ABRAMS JS, GLEICH GJ. Granulocyte/macrophage colony-stimulaling factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991;174:745-748.
31. DUBUCQUOI S, DESREUMAUX P, JANIN A, KLEIN O, GOLDMAN M, TAVERNIER J et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med 1994;179:703-708.
32. HAMID Q, BARKANS J, MENG Q, YING S, ABRAMS JS, KAY AB et al. Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood 1992;80:1496-1501.
33. YOUSEFI S, HEMMANN S, WEBER M, HÖLZER C, HARTUNG K, BLASER K et al. IL-8 is expressed by human peripheral blood eosinophils. J Immunol 1995;154:5481-5490.
34. WONG DT, WELLER PF, GALLI SJ, ELOVIC A, RAND TH, GALLAGHER GT et al. Human eosinophils express transforming growth factor alpha. J Exp Med 1990;172:673-681.
35. YING S, MENG Q, TABORDA-BARATA L, CORRIGAN CJ, BARKANS J, ASSOUFI B et al. Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. Eur J Immunol 1996;26:70-76.
36. HAN SJ, KIM JH, NOH YJ, CHANG HS, KIM CS, KIM KS et al. Interleukin (IL)-5 downregulates tumor necrosis factor (TNF)-induced eotaxin messenger RNA (mRNA) expression in eosinophils. Induction of eotaxin mRNA by TNF and IL-5 in eosinophils. Am J Respir Cell Mol Biol 1999;21:303-310.
37. NAKAJIMA T, YAMADA H, IIKURA M, MIYAMASU M, IZUMI S, SHIDA H et al. Intracellular localization and release of eotaxin from normal eosinophils. FEBS Lett 1998;434:226-230.
38. GARCIA-ZEPEDA EA, ROTHENBERG ME, OWNBEY RT, CELESTIN J, LEDER P, LUSTER AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449-456.
39. COSTA JJ, MATOSSIAN K, RESNICK MB, BEIL WJ, WONG DT, GORDON JR et al. Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory proiein-1 alpha. J Clin Invest 1993;91:2673-2684.
40. HÅKANSSON L, CARLSON M, STÅLENHEIM G, VENGE P. Migratory responses of eosinophil and neutrophil granulocytes from patients with asthma. J Allergy Clin Immunol 1990;85:743-750.
41. GRIFFIN E, HÅKANSSON L, FORMGREN H, JÖRGENSEN K, VENGE P. Increased chemokinetic and chemotactic responses of eosinophils in asthmatic patients. Allergy 1991;46:255-265.
42. HAKANSSON L, HEINRICH C, RAK S, VENGE P. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy. J Allergy Clin Immunol 1997;99:551-562.
43. CARLSON M, HÅKANSSON L, KÄMPE M, STÅLENHEIM G, PETERSON C. Degranulation of eosinophils from pollen-atopic patients with asthma is increased during pollen-season. J Allergy Clin Immunol 1992;89:131-139.
44. WALKER C, VIRCHOW J-C, BRUIJNZEEL PLB, BLASER K. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol 1991;146:1829-1835.
45. TILL S, LI B, DURHAM S, HUMBERT M, ASSOUFI B, HUSTON D et al. Secretion of the eosinophil-active cytokines interleukin-5, granulocyte/macrophage colony-stimulating factor and interleukin-3 by broncho alveolar lavage CD4+ and CD8+ T cell lines in atopics asthmatics, and atopic and non atopic controls. Eur J Immunol 1995;25:2727-2731.
46. SANMUGALINGHAM D, De VRIES E, GAUNTLETT R, SYMON FA, BRADDING P, WARDLAW AJ. Interleukin-5 enhances eosinophil adhesion to bronchial epithelial cells. Clin Exp All 2000;30:255-263.
47. HAKANSSON L, VENGE P. Priming of eosinophil and neutrophil migratory responses by interleukin-3 and interleukin-5. APMIS 1994;102:1-7.
48. SCHWEIZER RC, WELMERS BAC, RAAIJMAKERS JAM, ZANEN P, LAMMERS J-WJ, KOENDERMAN L. RANTES-and interleukin-8-induced responses in normal human eosinophils: effects of priming with interleukin-5. Blood 1994;83:3697-3704.
49. CARLSON M, PETERSON C, VENGE P. The influence of IL-3, IL-5 and GM-CSF on normal human eosinophil and neutrophil C3b-induced degranulation. Allergy 1993;48:437-442.
50. MACARI DMT, TEIXEIRA MM, ANSARI T, JEFFERY PK, HELLEWELL PG. Priming and induction of eosinophil trafficking in guinea-pig cutaneous inflammation by tumour necrosis factor α. Br J Pharmacol 1998;125:1228-1235.
51. NAGATA M, FUKUDA T, NUMAO T, MAKINO S, DOHI Y. Tumor necrosis alpha induces migration of human eosinophils. Arerugi 1993;42:549-555.
52. BURKE-GAFFNEY A, HELLEWELL PG. Eotaxin stimulates eosinophil adhesion to human lung microvascular endothelial cells. Biochem Biophys Res Commun 1996;227:35-40.
53. CARLOS TM, HARLAN JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-2101.
54. EBISAWA M, BOCHNER BS, GEORAS SN, SCHLEIMER RP. Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1b-induced transendothelial migration. J Immunol 1992;149:4021-4028.
55. ULFMAN LH, JOOSTEN DPH, van der LINDEN JAM, LAMMERS J-WJ, ZWAGINGA JJ, KOENDERMAN L. IL-8 induces a transient arrest of rolling eosinophils on human endothelial cells. J Immunol 2001;166:588-595.
56. 5β1 integrin. J Immunol 2002;168;1380-1388.
57. BLOEMEN PGM, HENRICKS PAJ, NUKAMP FP. Review: Cell adhesion molecules and asthma. Clin Exp Allergy 1997;27:128-141.
58. ASAKURA H, KASHIO V, NAKAMURA K, SEKI M, DAI S, SHIRATO Y et al. Selective eosinophil adhesion to fibroblast via IFN-γ-induced galectin-9. J Immunol 2002;169:5912-5918.
59. BRUUNZEEL PLB. Eosinophil tissue mobilization in allergic disorders. Ann NY Acad Sci 1994;725:259-267.
60. CUVELIER SL, PATEL KD. Shear-dependent eosinophil transmigration on interleukin-4-stimulated endothelial cells: a role for endothelium-associated eotaxin-3. J Exp Med 2001;194:1699-1709.
61. YAMAMOTO H, SEDGWICK JB, VRTIS RF, BUSSE WW. The effect of transendothelial migration on eosinophil function. Am J Respir Cell Mol Biol 2000;23:379-388.
62. HOSHI H, OHNO I, HONMA M, TANNO Y, YAMAGUCHI K, TAMURA G et al. IL-5, IL-8 and GM-CSF immunostaining of sputum cells in bronchial asthma and chronic bronchitis. Clin Exp Allergy 1995;25:720-728.
63. BRADDING P, ROBERTS JA, BRITTEN KM, MONTEFORT S, DJUKANOVIC R, MUELLER R et al. Interleukin-4, -5, and -6 and tumor necrosis factor-α in normal and asthmatic airways: evidence for the human mastcell as a source of these cytokines. Am J Respir Cell Mol Biol 1994;10:471-480.
64. TERAN L, NOSO N, CARROLL M, DAVIES DE, HOLGATE S, SCHRÖDER J-M. Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. J Immunol 1996;157:1806-1812.
65. GUTIERREZ-RAMOS JC, LLOYD C, GONZALO J-A. Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. Immunol Today 1999;20:500-504.
66. MACDERMOTT RP, SANDERSON IR, REINECKER H-C. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 1998;4:54-67.
67. KAPLAN AP, REDDIGAN SR, KUNA P. Chemokines and the allergic response. Exp Dermatol 1995;4:260-265.
68. BISCHOFF SC, LORENTZ A, SCHWENGBERG S, WEIER G, RAAB R, MANNS MP. Mast cells are an important cellular source of tumour necrosis factor-α in human intestinal tissue. Gut 1999;44:643-652.
69. TACHIMOTO H, BURDICK MM, HUDSON SA, KIKUCHI M, KONSTANTOPOULOS K, BOCHNER BS. CCR3-active chemokines promote rapid detachment of eosinophils from VCAM-1 in vitro. J Immunol 2000;165:2748-2754.
70. STOSSEL TP. The machinery of blood cell movements. Blood 1994;84:367-379.
71. FAY FS, GILBERT SH, BRUNDAGE RA. Calcium signalling during chemotaxis. In: Calcium waves, gradients and oscillations. Ciba Foundation Symposium 188, Chichester: Wiley, 1996:121-140.
72. PALECEK SP, HORWITZ AF, LAUFFENBURGER DA. Kinetic model for integrin-mediated adhesion release during cell migration. Ann Biomed Eng 1999;27:219-235.
73. SOUTHWICK FS, STOSSEL TP. Contractile proteins in leukocyte function. Sem Hematol 1983;20:305-321.
74. ZIMMERMAN N, ROTHENBERG ME. Receptor internalization is required for eotaxin-induced responses in human eosinophils. J Allergy Clin Immunol 2003;111:97-105.
75. RESNICK MB, WELLER PF. Mechanisms of eosinophil recruitment. Am J Respir Cell Mol Biol 1993;8:349-355.
76. LIU L, ZUURBIER AEM, MUL FPJ, VERHOEVEN AJ, LUTTER R, KNOL EF et al. Triple role of platelet-activating Factor in eosinophil migration across monolayers of lung epithelial cells: eosinophil chemoattractant and priming agent and epithelial cell activator. J Immunol 1998;161:3064-3070.
77. HOM JT, ESTRIDGE T. Antigen-induced recruitment of eosinophils: importance of CD44+ T-cells, IL-5, and mast cells. Clin Immunol Immunopathol 1994;73:305-311.
78. HORIE S, OKUBO Y, HOSSAIN M, SATO E, NOMURA H, KOYAMA S et al. Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Inter Med 1997;36:179-185.
79. PONATH PD, QIN S, RINGLER DJ, CLARC-LEWIS I, WANG J, KASSAM N et al. Cloning of the human eosinophil chemoattracant, eotaxin. J Clin Invest 1996;97:604-612.
80. FORSSMANN U, UGUCCIONI M, LOETSCHER P, DAHINDEN CA, LANGEN H, THELEN M et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997;185:2171-2176.
81. BANWELL ME, TOLLEY NS, WILLIAMS TJ, MITCHELL TJ. Regulation of human eotaxin-3/CCL26 expression: modulation by cytokines and glucocorticoids. Cytokine 2002;17:17-23.
82. KAMEYOSHI Y, DÖRSCHNER A, MALLET AI, CHRISTOPHERS E, SCHRÖDER J-M. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992;176:587-592.
83. SEHMI R, CROMWELL O, WARDLAW AJ, MOQBEL R, KAY AB. Interleukin-8 is a chemo-attractant for eosinophils purified from subjects with a blood eosinophilia but not from normal healthy subjects. Clin Exp Allergy 1993;23:1027-1036.
84. BANKS C, BATEMAN A, PAYNE R, JOHNSON P, SHERON N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003;199:28-35.
85. LAMPINEN M, RAK S, VENGE P. The role of interleukin-5, interleukin-8 and RANTES in the chemotactic attraction of eosinophils to the allergic lung. Clin Exp Allergy 1999;29:314-322.
86. LIU LY, SEDGWICK JB, BATES ME, VRTIS RF, GERN JE, KITA H et al. Decreased expression of membrane IL-5 receptorα on human eosinophils: 1. Loss of membrane IL-5 receptorα on airway eosinophils and inreased soluble IL-5 receptorα in the airway after allergen challenge. J Immunol 2002;169:6452-6458.
87. ERGER R, CASALE TB. Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium. Am J Physiol 1995;268:117-122.
88. LAMPINEN M, HÅKANSSON L VENGE P. Interleukin-2 inhibits eosinophil migration but is counteracted by IL-5 priming. Clin Exp Allergy 2001;31:249-258.
89. 4 is dependent on chemokinetic factors. J Leukoc Biol 1985;38:521-530.
90. WILKINSON PC. A requirement for albumin as a carrier for low molecular weight leukocyte chemotactic factors. Exp Cell Res 1976;103:415-420.
91. VALERIUS NH. Chemotaxis, spreading and oxidative metabolism of neutrophils: influence of albumin in vitro. Acta Pathol Microbiol lmmunol Scand 1983;91:43-49.
92. LAMPINEN M. Cytokine-regulated eosinophil migration in inflammatory disorders. Clinical and experimental studies. Thesis, Department of Medical Sciences, Clinical Chemistry, 2000.
93. POLUEKTOVA LY, HUGGLER GK, PATTERSON EB, KHAN MM. Involvement of protein kinase A in histamin-mediated inhibition of IL-2 mRNA expression in mouse splenocytes. Immunopharmacology 1990;41:77-78.
94. YOSHIKAWA M, MATSUMOTO K, IIDA M, AKASAWA A, MORIYAMA H, SAITO H. Effect of extracellular matrix proteins on platelet-activating factor-induced eosinophil chemotaxis. Int Arch All Immunol 2002;128:3-11.
95. HOENSTEIN R, ADMON D, SOLOMON A, NORRIS A, MOQBEL R, LEVI-SCHAFFER F. Interleukin-2 activates human peripheral blood eosinophils. Cell Immunol 2001;210:116-124.
96. NOCKER RET, van der ZEE JS, WELLER FR, van OVERVELD FJ, JANSEN HM, OUT TA. Segmental allergen challenge induces plasma protein leakage into the airways of asthmatic subjects at 4 hours but not at 5 minutes after challenge. J Lab Clin Med 1999;134:74-82.
97. COLLINS DS, DUPURS R, GLEICH GJ, BARTEMES KR, KOH YY, POLLICE M et al. Immunoglobulin E-mediated increase in vascular permeability correlates with eosinophilic inflammation. Am Rev Respir Dis 1993;147:677-683.
98. LAMKHIOUED B, SOUSSI-GOUNNI A, HAMID Q, MANSOUR N, DELESPESSE G, RENZI PM. The CCR3 receptor is involved in eosinophil differentiation and is up-regulated by Th2 cytokines in CD34+ progenitor cells. J Immunol 2002;169:537-547.
99. STIRLING RG, van RENSEN EL, BARNES PJ, CHUNG KF. Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med 2001;164:1403-1409.
100. DENBURG JA. Hemopoietic progenitors and cytokines in allergic inflammation. Allergy 1998;53:22-26.
101. LINDEN M, SVENSSON C, ANDERSSON M, GREIFF L, ANDERSSON E, DENBURG JA et al. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis. Allergy 1999;54:212-219.
102. KAY AB. Asthma and inflammation. J Allergy Clin Immunol 1991;87:893-910.
103. MAKING S, FUKUDA T. Eosinophils and allergy in asthma. Allergy Proc 1995;16:13-21.
104. LECKIE MJ, ten BRINKE A, KHAN J, DIAMANT Z, O'CONNOR BJ, WALLS CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
105. BRVAN SA, O'CONNOR BJ, MATTI S, LECKIE MJ, KANABAR V, KHAN J et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2149-2153.
106. VENGE P, HÅKANSSON L. Current understanding of the role of the eosinophil granulocyte in asthma. Clin Exp Allergy 1991;21:31-37.
107. De MONCHY JGR, KAUFFMAN HF, VENGE P, KOETER GH, JANSEN HM, SLUITER HJ et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 1985;131:373-376.
108. CORRIGAN CJ, KAY AB. T cells, cytokines and asthma. AAAI/EAACI Cytokine Symposium, 1992:2-18.
109. WALKER C, VIRCHOW J-C, BRUIJNZEEL PLB, BLASER K. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol 1991;146:1829-1835.
110. SEMINARIO MC, BOCHNER BS. Expression and function of beta 1 integrins on human eosinophils. Mem Inst Oswaldo Cruz 1997; 92 (Suppl. 2):157-164.
111. VENGE J, LAMPINEN M, HÅKANSSON L, RAK S, VENGE P. Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. J Allergy Clin Immunol 1996;97:1110-1115.
112. SCHEERENS J, FOLKERTS G, Van DER LH, STERK PJ, CONROY DM, WILLIAMS TJ et al. Eotaxin levels and eosinophils in guinea pig broncho-alveolar lavage fluid are increased at the onset of a viral respiratory infection. Clin Exp Allergy 1999; 29 (Suppl. 2):74-77.
113. D'ARIENZO A, MANGUSO F, ASTARITA C, D'ARMIENTO FP, SCARPA R, GARGANO D et al. Allergy and mucosal eosinophil infilrate in ulcerative colitis. Scand J Gastroenterol 2000;6:624-631.
114. ELLIOTT SN, WALLACE JL. Neutrophil-mediated gastrointestinal injury. Can J Gastroenterol 1998;12:559-568.
115. INA K, KUSUGAMI K, YAMAGUCHI T, IMADA A, HOSOKAWA T, OHSUGA M et al. Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am J Gastroenterol 1997;92:1342-1346.
116. MADARA JL. Review article: Pathobiology of neutrophil interactions with intestinal epithelia. Aliment Pharmacol Ther 1997;11:57-63.
117. RAAB Y, GERDIN B, AHLSTEDT S, HALLGREN R. Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis. Gut 1993;34:1203-1206.
118. MATTHEWS AN, FRIEND DS, ZIMMERMAN N, SARAFI MN, LUSTER AD, PEARLMAN E et al. Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci 1998;95:6273-6278.
119. BISCHOFF SC, MEIER PN, TRAUTWEIN C, CETIN Y, MASCHEK H, STOLTE M et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996;28:1-13.
120. DUBUCQUOI S, JANIN A, KLEIN O, DESREUMAUX P, QUANDALLE P, CORTOT A et al. Activated eosinophils and interleukin-5 expression in early recurrence of Crohn's disease. Gut 1995;67:242-246.
121. CARVALHO AT, ELIA CC, De SOUZA HS, ELIAS PR, PONTES EL, LUKASHOK HP et al. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J Clin Gastroenterol 2003;36:120-125.
122. CARLSON M, RAAB Y, PETERSON C, HÄLLGREN R, VENGE P. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol 1999;94:1876-1883.
123. LUCK W, BECKER M, NIGGEMAN B, WAHN U. In vitro release of eosinophil cationic protein from peripheral eosinophils reflects disease activity in childhood Crohn disease and ulcerative colitis. Eur J Pediatr 1997;156:921-924.
124. SANGFELT P, CARLSON M, THÖRN M, LÖÖF L, RAAB R. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulceratice colitis and proctitis. Am J Gastroenterol 2001;96:1085-1090.
125. TAHA Y, CARLSON M, THÖRN M, LÖÖF L, RAAB R. Evidence of local eosinophil activation and altered mucosal permeability in collagenous colitis. Dig Dis Sci 2001;46:888-895.
126. DENIS M-A, LOUIS R, MALAISE M, BELAICHE J, LOUIS E. Increased response of blood eosinophils to various chemotactic agents in quiescent Crohn disease. Scand J Gastroent 2001;36:190-195.
127. KOIZUMI M, KING N, LOBB R, BENJAMIN C, PODOLSKY DK. Expession of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992;103:840-847.
128. MISHRA A, HOGAN SP, BRANDT E, WAGNER N, CROSSMAN MW, FOSTER PS et al. Enterocytc expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking. J Biol Chem 2002;277:4406-4412.
129. LAMPINEN M, CARLSON M, SANGFELT P, TAHA Y, THÖRN M, LÖÖF L et al. IL-5 and TNF-α participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci 2001;46:2004-2009.
130. REINECKER H-C, STEFFEN M, WITTHOEFT T, PFLUEGER F, SCHREIBER S, MACDERMOTT RP et al. Enhanced secretion of tumour necrosis factor-α, IL-6 and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-181.
131. SANGFELT P, CARLSON M, THÖRN M, XU SY, LÖÖF L, RAAB R. Local release of human neutrophil lipocalin (HNL), IL-8 and TNF-alpha is decreased as response to topical prednisolone treatment in distal ulcerative colitis and proctitis. Dig Dis Sci 2002;47:2064-2069.
132. EVANS RC, CLARKE L, HEATH P, STEPHENS S, MORRIS AI, RHODES JM. Treatment of ulcerative colitis with an engineered human anti-TNF alpha antibody CDP571. Aliment Pharmacol Ther 1999;11:1031-1035.
133. SIMON H-U, YOUSEFI S, SCHRANZ C, SCHAPOWAL A, BACHERT C, BLASER K, Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158:3902-3908.
134. WEDI B, RAAP U, LEWRICK H, KAPP A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997;100:536-543.
135. KANKAANRANTA H, LINDSAY MA, GIEMBYCZ MA, ZHANG X, MOILANEN E, BARNES PJ. Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol 2000;106:77-83.
136. MATSUMOTO K, SCHLEIMER RP, SAITO H, IIKURA Y, BOCHNER BS. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 1995;86:1437-1443.
137. TSUYUKI S, BERTRAND C, ERARD F. Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. J Clin Invest 1995;96:2924-293L
138. LETUVE S, DRUILHE A, GRANDSAIGNE M, AUBIER M, PRETOLANI M. Involvement of easpases and of mitochondria in Fas ligation-induced eosinophil apoptosis: modulation by interleukin-5 and interferon-gamma. J Leukoc Biol 2001;70:767-775.
139. STERN M, MEAGHER L, SAVILL J, HASLETT C. Apoptosis in human eosinophils: programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 1992;148:3543.
140. HER E, FRAZER J, AUSTEN KF, OWEN WF. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. J Clin Invest 1991;88:1982-1987.
141. YOUSER S, HOESSLI DC, BLASER K, MILLS GB, SIMON H-U. Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med 1996;183:1407-1414.
142. DIBBERT B, DAIGLE I, BRAUN D, SCHRANZ C, WEBER M, BLASER K et al. Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood 1998;92:778-783.
143. SIMON H-U. Eosinophil apoptosis-pathophysiologic and therapeutic implications. Allergy 2000;55:910-915.
144. HIGASHIMOTO I, CHIHARA J, KAKAZU T, KAWABATA M, NAKAJIMA S, OSAME M. Regulation of eosinophil cell death by adhesion to fibronectin. Int Arch All Immunol 1996;111:66-69.
145. SCHLEIMER RP. Glucocorticosteroids. Their mechanisms of action and use in allergic diseases. In: MIDDLETON E, REED CE, ELLIS EF, eds. Allergy principles and practice. St Louis: Mosby, 1993:893-925.
146. SCHLEIMER RP, BECK L, SCHWEIBERT L. Inhibition of inflammatory cell recruitment by glucocorticoidcs: cytokines as primary targets. In: SCHLEIMER RP, BUSSE WW, O'BYRNE P, ed. Inhaled glucocorticoids in asthma. Mechanisms and clinical actions. New York: Marcel Dekker, 1997:203-238.
147. MEAGHER LC, COUSIN JM, SECKL JR, HASLETT C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422-4428.
148. NUTKU E, ZHUANG Q, SOUSSI-GOUNNI A, ARIS F, MAZER BD, HAMID Q. Functional expression of IL-12 receptor by human eosinophils: IL-12 promotes eosinophil apoptosis. J Immunol 2001;167:1039-1046.
149. BANNER KH, PAGE CP. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Respir J 1995;8:996-1000.
150. YASUI K, HU B, NAKAZAWA T, AGEMATSU K, KOMIYAMA A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 1997;100:1677-1684.
151. OHTA K, SAWAMOTO S, NAKAJIMA M, KUBOTA S, TANAKA Y, MIYASAKA T et al. The prolonged survival of human eosinophils with interleukin-5 and its inhibition by theophylline via apoptosis. Clin Exp All 1996;26:10-15.